Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open, Multicenter, Phase II Study to Investigate the Efficacy and Safety of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

NCT04705090 is registered in ClinicalTrials.gov with Shanghai YingLi Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT04705090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04705090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open, Multicenter, Phase II Study to Investigate the Efficacy and Safety of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
Lead sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2021
Completion date
June 30, 2023
Enrollment
90 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ptcl